The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Open accessAbstract
Alzheimer disease (AD) is the most common cause of dementia in adults. The current therapy for AD has only moderate efficacy in controlling symptoms, and it does not cure the disease. Recent studies have suggested that abnormal hyperphosphorylation of tau in the brain plays a vital role in the molecular pathogenesis of AD and in neurodegeneration. This article reviews the current advances in understanding of tau protein, regulation of tau phosphorylation, and the role of its abnormal hyperphosphorylation in neurofibrillary degeneration. Furthermore, several therapeutic strategies for treating AD on the basis of the important role of tau hyperphosphorylation in the pathogenesis of the disease are described. These strategies include (1) inhibition of glycogen synthase kinase-3beta (GSK-3beta), cyclin-dependent kinase 5 (cdk5), and other tau kinases; (2) restoration of PP2A activity; and (3) targeting tau O-GlcNAcylation. Development of drugs on the basis of these strategies is likely to lead to disease-modifying therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Self-citationA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Cited by
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Metals, oxidative stress and neurodegenerative disorders
Jomova, K., Vondrakova, D., Lawson, M., & Valko, M. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0563-x · Cited by 1,052
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 641
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 553
Mitochondrial dysfunction and oxidative stress in aging and cancer
Kudryavtseva, A. V., Krasnov, G. S., Dmitriev, A. A., Alekseev, B. Y., Kardymon, O. L., Sadritdinova, A. F., Fedorova, M. S., Pokrovsky, A. V., Melnikova, N. V., Kaprin, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9821 · Cited by 543
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
Heckmann, B. L., Teubner, B. J. W., Tummers, B., Boada-Romero, E., Harris, L., Yang, M., Guy, C. S., Zakharenko, S. S., & Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.05.056 · Cited by 503
“The incidence of tau phosphorylation increases as disease progresses and leads to microtubule de-stabilization and failure of the microtubule architecture, especially within neuronal axons (Frost et al., 2015; Gong and Iqbal, 2008; Noble et al., 2013).”
Structure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., & Ripova, D. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/731526 · Cited by 468
Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease
Eftekharzadeh, B., Daigle, J. G., Kapinos, L. E., Coyne, A., Schiantarelli, J., Carlomagno, Y., Cook, C., Miller, S. J., Dujardin, S., Amaral, A. S., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.07.039 · Cited by 460
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2009) · Brain · doi:10.1093/brain/awp099 · Cited by 439
“…of tau in Alzheimer’s disease remain elusive, although Ab toxicity (Blurton-Jones and Laferla, 2006), deregulation of protein kinases and phosphatases (Gong and Iqbal, 2008; Pei et al., 2008), and mitochondrial oxidative stress (Lee et al., 2005; Melov et al., 2007) have been implicated.”
BackgroundSelf-citationRedox regulation by NRF2 in aging and disease
Schmidlin, C. J., Dodson, M. B., Madhavan, L., & Zhang, D. D. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.016 · Cited by 434
Butkinaree, C., Park, K., & Hart, G. W. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.018 · Cited by 415
Reassessing the amyloid cascade hypothesis of Alzheimer's disease
Pimplikar, S. W. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.015 · Cited by 375
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 309
Targeting protein kinases in central nervous system disorders
Chico, L. K., Van Eldik, L. J., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 298
Physiological and pathological phosphorylation of tau by Cdk5
Kimura, T., Ishiguro, K., & Hisanaga, S.-I. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00065 · Cited by 297
Endoplasmic reticulum stress and inflammation in the central nervous system
Sprenkle, N. T., Sims, S. G., Sánchez, C. L., & Meares, G. P. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0183-y · Cited by 294
van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
Role of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Chen, J.-Q., Cammarata, P. R., Baines, C. P., & Yager, J. D. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.06.001 · Cited by 264
Multi-Target Drugs: The Trend of Drug Research and Development
Lu, J.-J., Pan, W., Hu, Y.-J., & Wang, Y.-T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040262 · Cited by 259
Luo, H.-B., Xia, Y.-Y., Shu, X.-J., Liu, Z.-C., Feng, Y., Liu, X.-H., Yu, G., Yin, G., Xiong, Y.-S., Zeng, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417548111 · Cited by 236
Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
Roy, R. G., Mandal, P. K., & Maroon, J. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00486 · Cited by 194
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185
Janczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., Brothers, S. P., & Wahlestedt, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805436115 · Cited by 183
“We also observed that there was a significant effect of the treatment on the percent of mice guided to the goal box on training day 1 compared with training day 4 [F(2, 24) = 16.”
BackgroundRetractedFrom Chronic Cerebral Hypoperfusion to Alzheimer-Like Brain Pathology and Neurodegeneration
Zhao, Y., & Gong, C.-X. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0127-9 · Cited by 180
Self-citationActivation of mTOR: a culprit of Alzheimer’s disease?
Cai, Z., Zhou, Y., Xiao, M., Yan, L.-J., & He, W. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75717 · Cited by 161
Tau Oligomers and Fibrils Induce Activation of Microglial Cells
Morales, I., Jiménez, J. M., Mancilla, M., & Maccioni, R. B. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-131843 · Cited by 160
An Overview on the Clinical Development of Tau-Based Therapeutics
Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
“A number of candidate kinases have been proposed to play a role in the posttranslational phosphorylation of tau (Mazanetz and Fischer 2007; Gong and Iqbal 2008; Hanger et al. 2009).”
BackgroundTau directs intracellular trafficking by regulating the forces exerted by kinesin and dynein teams
Chaudhary, A. R., Berger, F., Berger, C. L., & Hendricks, A. G. (2018) · Traffic · doi:10.1111/tra.12537 · Cited by 118
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
The Many Faces of Astrocytes in Alzheimer's Disease
Monterey, M. D., Wei, H., Wu, X., & Wu, J. Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619626 · Cited by 117
Cao, Q., Wang, W., Williams, J. B., Yang, F., Wang, Z.-J., & Yan, Z. (2020) · Science Advances · doi:10.1126/sciadv.abc8096 · Cited by 108
“Since Sgk1 is capable of phosphorylating the microtubuleassociated protein tau (37), which might contribute to tau hyperphosphorylation, a pathological hallmark of AD (38, 39), we evaluated the effect of Sgk1 inhibitor on hyperphosphorylated tau.”
BackgroundResultLi, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Alzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex
Zhang, J., Li, H., Yabut, O., Fitzpatrick, H., D'Arcangelo, G., & Herrup, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5628-09.2010 · Cited by 96
“…hyperphosphorylated tau is a major constituent of the neurofibrillary tangles found in Alzheimer’s and other dementias, inhibition of Cdk5 activity has been proposed as a therapeutic approach to slowing the advance of the disease (Camins et al., 2006; Gong and Iqbal, 2008; Kaminosono et al., 2008).”
BackgroundHsu, P.-H., Lin, Y.-T., Chung, Y.-H., Lin, K.-J., Yang, L.-Y., Yen, T.-C., & Liu, H.-L. (2018) · Scientific Reports · doi:10.1038/s41598-018-31071-8 · Cited by 70
Sen, T., Saha, P., Jiang, T., & Sen, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916895117 · Cited by 68
Del Amo, L., Cano, A., Ettcheto, M., Souto, E. B., Espina, M., Camins, A., García, M. L., & Sánchez-López, E. (2021) · Applied Sciences · doi:10.3390/app11094305 · Cited by 67
Inflammation as common link to progressive neurological diseases
Dias-Carvalho, A., Sá, S. I., Carvalho, F., Fernandes, E., & Costa, V. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03628-8 · Cited by 60
Li, S.-Q., Yu, Y., Han, J.-Z., Wang, D., Liu, J., Qian, F., Fan, G.-H., Bucala, R., & Ye, R. D. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0396-3 · Cited by 59
“Tau hyperphosphorylation is a major pathological feature of neurodegenerative disorders such as AD [18].”
BackgroundLILRB2-mediated TREM2 signaling inhibition suppresses microglia functions
Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00550-y · Cited by 54
Further understanding of tau phosphorylation: implications for therapy
Medina, M., & Avila, J. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1000864 · Cited by 41
“As an alternative to kinase inhibition, activation of phosphatases has also been proposed as a strategy for reducing tau phosphorylation, especially in the case of protein phosphatase 2A (PP2A), which seems to be the main brain phosphatase involved in tau phosphorylation [54].”
BackgroundRole of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
Zimmer, E. R., Leuzy, A., Bhat, V., Gauthier, S., & Rosa-Neto, P. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-6 · Cited by 30
“The major phosphatase in the human brain [5], PP2A accounts for the overwhelming majority of tau dephosphorylation.”
BackgroundMohamed, S. M., Shalaby, M. A., Al‑Mokaddem, A. K., El-Banna, A. H., EL-Banna, H. A., & Nabil, G. (2023) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2023.102234 · Cited by 21
Hamilton, K., Morrow, K., Markantoni, E., & Harvey, J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15980 · Cited by 10
Metadata
- Authors
- Gong, C.-X., & Iqbal, K.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-10-01
- Volume
- 15
- Issue
- 23
- Pages
- 2321-2328
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2011485908
- Cited by
- 644
- References
- 140
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.